vs
LEGALZOOM.COM, INC.（LZ）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是LEGALZOOM.COM, INC.的1.1倍（$207.3M vs $190.3M），LEGALZOOM.COM, INC.净利率更高（3.2% vs -62.0%，领先65.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 17.7%），LEGALZOOM.COM, INC.自由现金流更多（$28.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.5%）
LegalZoom是2001年成立的美国在线法律科技与服务企业，依托独立律师网络、旗下自营律所，结合自助服务技术与专属顾问，为用户提供线上法律服务。核心业务涵盖遗嘱、生前信托设立，营业执照、许可证办理等商事合规服务，以及版权登记、商标申请，同时还提供律师推荐等相关配套服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LZ vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $190.3M | $207.3M |
| 净利润 | $6.1M | $-128.6M |
| 毛利率 | 67.6% | — |
| 营业利润率 | 6.6% | -54.7% |
| 净利率 | 3.2% | -62.0% |
| 营收同比 | 17.7% | 25.9% |
| 净利润同比 | -52.9% | 3.5% |
| 每股收益（稀释后） | $0.03 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $190.3M | $207.3M | ||
| Q3 25 | $190.2M | $159.9M | ||
| Q2 25 | $192.5M | $166.5M | ||
| Q1 25 | $183.1M | $139.3M | ||
| Q4 24 | $161.7M | $164.6M | ||
| Q3 24 | $168.6M | $139.5M | ||
| Q2 24 | $177.4M | $147.0M | ||
| Q1 24 | $174.2M | $108.8M |
| Q4 25 | $6.1M | $-128.6M | ||
| Q3 25 | $4.5M | $-180.4M | ||
| Q2 25 | $-266.0K | $-115.0M | ||
| Q1 25 | $5.1M | $-151.1M | ||
| Q4 24 | $12.9M | $-133.2M | ||
| Q3 24 | $11.1M | $-133.5M | ||
| Q2 24 | $1.3M | $-131.6M | ||
| Q1 24 | $4.7M | $-170.7M |
| Q4 25 | 67.6% | — | ||
| Q3 25 | 67.3% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.7% | — | ||
| Q4 24 | 67.0% | — | ||
| Q3 24 | 67.5% | — | ||
| Q2 24 | 64.1% | — | ||
| Q1 24 | 60.7% | — |
| Q4 25 | 6.6% | -54.7% | ||
| Q3 25 | 3.4% | -106.9% | ||
| Q2 25 | -1.6% | -64.8% | ||
| Q1 25 | 4.9% | -102.6% | ||
| Q4 24 | 8.1% | -74.3% | ||
| Q3 24 | 9.6% | -94.6% | ||
| Q2 24 | 0.6% | -79.1% | ||
| Q1 24 | 2.9% | -151.9% |
| Q4 25 | 3.2% | -62.0% | ||
| Q3 25 | 2.4% | -112.8% | ||
| Q2 25 | -0.1% | -69.0% | ||
| Q1 25 | 2.8% | -108.5% | ||
| Q4 24 | 7.9% | -80.9% | ||
| Q3 24 | 6.6% | -95.7% | ||
| Q2 24 | 0.7% | -89.5% | ||
| Q1 24 | 2.7% | -156.8% |
| Q4 25 | $0.03 | $-1.28 | ||
| Q3 25 | $0.02 | $-1.81 | ||
| Q2 25 | $0.00 | $-1.17 | ||
| Q1 25 | $0.03 | $-1.57 | ||
| Q4 24 | $0.07 | $-1.34 | ||
| Q3 24 | $0.06 | $-1.40 | ||
| Q2 24 | $0.01 | $-1.52 | ||
| Q1 24 | $0.02 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $203.1M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $171.9M | $-80.0M |
| 总资产 | $511.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $203.1M | $421.0M | ||
| Q3 25 | $237.2M | $202.5M | ||
| Q2 25 | $217.0M | $176.3M | ||
| Q1 25 | $210.0M | $127.1M | ||
| Q4 24 | $142.1M | $174.0M | ||
| Q3 24 | $112.5M | $150.6M | ||
| Q2 24 | $118.8M | $480.7M | ||
| Q1 24 | $228.1M | $112.3M |
| Q4 25 | $171.9M | $-80.0M | ||
| Q3 25 | $201.9M | $9.2M | ||
| Q2 25 | $194.1M | $151.3M | ||
| Q1 25 | $187.2M | $144.2M | ||
| Q4 24 | $93.3M | $255.0M | ||
| Q3 24 | $60.1M | $346.8M | ||
| Q2 24 | $60.8M | $432.4M | ||
| Q1 24 | $167.9M | $140.3M |
| Q4 25 | $511.5M | $1.5B | ||
| Q3 25 | $551.1M | $1.2B | ||
| Q2 25 | $543.0M | $1.3B | ||
| Q1 25 | $532.7M | $1.3B | ||
| Q4 24 | $373.9M | $1.5B | ||
| Q3 24 | $348.8M | $1.5B | ||
| Q2 24 | $359.5M | $1.6B | ||
| Q1 24 | $459.7M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $28.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 14.7% | -48.6% |
| 资本支出强度资本支出/营收 | 3.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.63× | — |
| 过去12个月自由现金流最近4个季度 | $147.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $34.1M | $-99.8M | ||
| Q3 25 | $54.2M | $-91.4M | ||
| Q2 25 | $39.1M | $-108.3M | ||
| Q1 25 | $50.7M | $-166.5M | ||
| Q4 24 | $42.6M | $-79.3M | ||
| Q3 24 | $31.6M | $-67.0M | ||
| Q2 24 | $27.2M | $-77.0M | ||
| Q1 24 | $34.2M | $-190.7M |
| Q4 25 | $28.0M | $-100.8M | ||
| Q3 25 | $47.0M | $-92.7M | ||
| Q2 25 | $31.6M | $-110.7M | ||
| Q1 25 | $41.3M | $-167.8M | ||
| Q4 24 | $35.9M | $-79.5M | ||
| Q3 24 | $22.0M | $-68.6M | ||
| Q2 24 | $17.4M | $-79.0M | ||
| Q1 24 | $24.7M | $-193.9M |
| Q4 25 | 14.7% | -48.6% | ||
| Q3 25 | 24.7% | -58.0% | ||
| Q2 25 | 16.4% | -66.5% | ||
| Q1 25 | 22.6% | -120.5% | ||
| Q4 24 | 22.2% | -48.3% | ||
| Q3 24 | 13.0% | -49.2% | ||
| Q2 24 | 9.8% | -53.7% | ||
| Q1 24 | 14.2% | -178.2% |
| Q4 25 | 3.2% | 0.5% | ||
| Q3 25 | 3.8% | 0.8% | ||
| Q2 25 | 3.9% | 1.5% | ||
| Q1 25 | 5.1% | 1.0% | ||
| Q4 24 | 4.1% | 0.1% | ||
| Q3 24 | 5.7% | 1.2% | ||
| Q2 24 | 5.6% | 1.4% | ||
| Q1 24 | 5.4% | 3.0% |
| Q4 25 | 5.63× | — | ||
| Q3 25 | 12.03× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 9.89× | — | ||
| Q4 24 | 3.31× | — | ||
| Q3 24 | 2.86× | — | ||
| Q2 24 | 20.74× | — | ||
| Q1 24 | 7.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LZ
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
